Skip to main content

Question for Department of Health

UIN HL3851, tabled on 17 December 2014

To ask Her Majesty’s Government what representations they have received about access to Duodopa for people in the advanced stages of Parkinson's disease; and what responses they have made.

Answered on

5 January 2015

We have received a number of representations from hon. Members, noble Lords, patient groups and members of the public about access to Duodopa for the treatment of advanced Parkinson’s disease on the National Health Service.

Our responses have made clear that NHS England has responsibility for commissioning adult specialist neurosciences services, including the majority of services for patients with Parkinson’s disease and have set out NHS England’s position on this issue at the time of writing.